A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet

NCT00566267 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipidemia

Interventions

DRUG: simvastatin 20 mg/ezetimibe

Sponsor

Merck Sharp & Dohme LLC